Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ONCY pelareorep + CD3 bispecific antibody true-killer combo

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Sep 14, 2024 7:39pm

76 Views

Post# 36224099

RE:RE:ONCY pelareorep + CD3 bispecific antibody true-killer combo

Today the CD3 protein is a hot target and the addition of ONCY's pelareorep to the CD3 bispecific potentiates the effectiveness of both agents due to improved T-cell quality from pelareorep's remodeling of the TME, and an appreciably improved T-cell infiltration, resulting in a greater effectiveness in the killing of the tumor cells.

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec